---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-259961"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-10-20T23:59:59+00:00"
generated_at: "2026-06-09T18:15:44.462715+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharmaceuticals appoints Richard J. Daly as CEO, effective Jan 1, 2024

## Summary
- Patrick J. McEnany retires as CEO effective Dec 31, 2023, remains Chairman of the Board.
- Richard J. Daly, Board member since 2015, named CEO; previously President at CARsgen, CEO of Neuralstem.
- Daly receives base salary of $750,000, bonus up to 75% of base, stock options for 1,365,319 shares at $13.30.
- Options and restricted stock units vest in 5 annual installments starting Jan 1, 2025.
- Daly to become consultant from Dec 1, 2023 for transition with McEnany.

## SEC filing metadata
- accession: 0001193125-23-259961
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-10-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523259961/0001193125-23-259961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523259961/d514248d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-259961
- JSON: https://secwatch.observer/filing/0001193125-23-259961.json
- Plain text: https://secwatch.observer/filing/0001193125-23-259961.txt

## Key facts
- Executive change
  Patrick J. McEnany retired as Chairman of the Board at CATALYST PHARMACEUTICALS, INC..
  - Action: retired
  - Role: Chairman of the Board
  source text: The Company’s current CEO, Patrick J. McEnany, will continue to serve as the Company’s CEO until December 31, 2023 and, following his retirement as the Company’s CEO, will continue to serve on the Company’s Board of Directors (“ Board ”) as the non-executive Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523259961/0001193125-23-259961-index.htm
- Executive change
  Richard J. Daly was appointed as Chief Executive Officer at CATALYST PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the appointment of Richard J. Daly, 62, as its Chief Executive Officer (“ CEO ”), to become effective on January 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523259961/0001193125-23-259961-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.